rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lineage Cell Therapeutics, Inc.

LCTX · NYSE American

Health CareBiotechnologyNot moving yet

LCTX stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 26 weeks. It is 21.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 26
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$49K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
128 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$5.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Brian M. CulleyPresident and CEObought15,000at $1.6312 Mar 2026filed 12 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders128+6 on the quarter
New · exited38 · 33
Reported value$146.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BROADWOOD CAPITAL INCunchanged · filed 14 Aug 202649,560,992$64.9M00.0%
BlackRock, Inc.added · filed 7 Aug 202613,186,895$17.3M+9,322,138+241.2%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20269,054,918$11.9M+736,233+8.9%
Defender Capital, LLC.reduced · filed 9 Jul 20266,598,899$8.6M-130,700−1.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20265,299,457$6.9M+2,776,343+110.0%
FIFTH THIRD BANCORPunchanged · filed 5 Aug 20264,600,000$6.0M00.0%
MILLENNIUM MANAGEMENT LLCreduced · filed 14 Aug 20263,018,567$4.0M-2,542,807−45.7%
STATE STREET CORPadded · filed 7 Aug 20262,314,180$3.0M+1,224,069+112.3%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 20261,668,629$2.2M+344,471+26.0%
NORTHERN TRUST CORPadded · filed 13 Aug 20261,656,651$2.2M+1,157,524+231.9%
31 Mar 2023 – 30 Jun 2026
92110127Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Angus C. Russell Company insiderDirector · last 1 Jul 20261 · 1
Anula Jayasuriya Company insiderDirector · last 1 Jul 20261 · 0
Deborah J. Andrews Company insiderDirector · last 1 Jul 20265 · 1
Dipti Amin Company insiderDirector · last 1 Jul 20261 · 0
Michael H. Mulroy Company insiderDirector · last 1 Jul 20262 · 0
Neal C. Bradsher Company insiderDirector, 10% owner · last 1 Jul 20268 · 0
Brian M. Culley Company insiderPresident and CEO · last 12 Mar 20266 · 1
George A. Samuel III Company insiderGeneral Counsel and Secretary · last 5 Mar 20261 · 0
Jill Ann Howe Company insiderChief Financial Officer · last 5 Mar 20262 · 0
Broadwood Capital Inc Company insider10% owner · last 27 Jan 202510 · 0
Don M. Bailey Company insiderDirector · last 1 Jul 20241 · 0
BROADWOOD PARTNERS, L.P. Company insiderDirector, 10% owner · last 6 Feb 20249 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-252%
Free cash flow marginFY 2025 · to 31 Dec 2025-134%
Return on capital employedFY 2025 · to 31 Dec 2025-36.2%
Research spendFY 2025 · to 31 Dec 2025122%
Share count trendFY 2025 · to 5 Mar 20262.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$40.8M
Free cash flowFY 2025 · to 31 Dec 2025−$19.4M

Analyst forecasts

No analyst forecasts yet.